ATE412667T1 - Langwirkende fusionspeptidinhibitoren gegen hiv- infektion - Google Patents

Langwirkende fusionspeptidinhibitoren gegen hiv- infektion

Info

Publication number
ATE412667T1
ATE412667T1 AT06023309T AT06023309T ATE412667T1 AT E412667 T1 ATE412667 T1 AT E412667T1 AT 06023309 T AT06023309 T AT 06023309T AT 06023309 T AT06023309 T AT 06023309T AT E412667 T1 ATE412667 T1 AT E412667T1
Authority
AT
Austria
Prior art keywords
long
virus
hiv infection
fusion peptide
against hiv
Prior art date
Application number
AT06023309T
Other languages
English (en)
Inventor
John Erickson
Dominique P Bridon
Martin Robitaille
Grant A Kraft
Dong Xie
Elena Afonia
Jun Liang
Meyer Sandra De
Original Assignee
Conjuchem Biotechnologies Inc
John Erickson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Biotechnologies Inc, John Erickson filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE412667T1 publication Critical patent/ATE412667T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06023309T 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion ATE412667T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31

Publications (1)

Publication Number Publication Date
ATE412667T1 true ATE412667T1 (de) 2008-11-15

Family

ID=23132509

Family Applications (3)

Application Number Title Priority Date Filing Date
AT02729737T ATE295370T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptid-inhibitoren für hiv- infektion
AT04015696T ATE345353T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
AT06023309T ATE412667T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT02729737T ATE295370T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptid-inhibitoren für hiv- infektion
AT04015696T ATE345353T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion

Country Status (11)

Country Link
US (2) US7741453B2 (de)
EP (1) EP1390399B1 (de)
JP (2) JP4463545B2 (de)
AT (3) ATE295370T1 (de)
AU (1) AU2002302277A1 (de)
CA (1) CA2448891A1 (de)
DE (3) DE60216151T2 (de)
DK (1) DK1479691T3 (de)
ES (2) ES2242860T3 (de)
PT (1) PT1479691E (de)
WO (1) WO2002096935A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1179012B2 (de) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
NZ543122A (en) * 2003-03-24 2008-07-31 Sequoia Pharmaceuticals Inc An HIV fusion inhibitor peptide covalently linked to a blood protein
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CN101687911A (zh) * 2007-05-16 2010-03-31 康久化学生物技术公司 抗病毒肽的半胱磺酸衍生物
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
KR100358209B1 (ko) 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
AU3370795A (en) 1994-08-15 1996-03-07 B-Level Corp. Auxiliary surface-forming member for construction elements
CA2220339C (en) 1995-05-10 2009-10-13 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
ATE406577T1 (de) 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
DE69812727D1 (de) 1997-11-07 2003-04-30 Conjuchem Inc Opioid-konjugate mit endogenen Trägerproteinen
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
JP2003529319A (ja) 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
EP1179012B2 (de) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1171582A2 (de) 1999-05-17 2002-01-16 Conjuchem, Inc. Lang wirksame antiangiogene peptide
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP1235618A2 (de) 1999-09-07 2002-09-04 Conjuchem, Inc. In vivo biokonjugierung an pulmonären oder blutkomponenten
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
DE60037450T2 (de) 1999-12-16 2008-12-04 Whitehead Institute For Biomedical Research, Cambridge Fünf-helix protein
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
CN1327897C (zh) 2002-09-24 2007-07-25 重庆前沿生物技术有限公司 Hiv感染的肽衍生物融合抑制剂
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
AU2003299085B2 (en) 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
US20050113292A1 (en) 2003-07-18 2005-05-26 Vanderbilt University Compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like
ES2347902T3 (es) 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
CA2565658A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
AU2006329215A1 (en) 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
DK1479691T3 (da) 2007-03-12
DE60216151D1 (de) 2006-12-28
ES2242860T3 (es) 2005-11-16
DE60204137T2 (de) 2006-01-26
US7741453B2 (en) 2010-06-22
JP4463545B2 (ja) 2010-05-19
WO2002096935A3 (en) 2003-10-02
JP2008308506A (ja) 2008-12-25
EP1390399B1 (de) 2005-05-11
DE60204137D1 (de) 2005-06-16
EP1390399A2 (de) 2004-02-25
ES2277173T3 (es) 2007-07-01
AU2002302277A1 (en) 2002-12-09
ATE295370T1 (de) 2005-05-15
US20110166061A1 (en) 2011-07-07
DE60229677D1 (de) 2008-12-11
HK1071379A1 (en) 2005-07-15
JP2005500274A (ja) 2005-01-06
PT1479691E (pt) 2007-02-28
WO2002096935A2 (en) 2002-12-05
US20050065075A1 (en) 2005-03-24
ATE345353T1 (de) 2006-12-15
DE60216151T2 (de) 2007-09-27
CA2448891A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ATE345353T1 (de) Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
DE69738535D1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
DE602006015861D1 (de) Antivirale verbindungen
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE541844T1 (de) Antivirale verbindungen
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
EP0652011A4 (de) Prophylaktisches mittel und arzneimittel für virale erkrankungen der atemwege.
DK1334119T3 (da) Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
WO2004052905A3 (en) Antiviral nucleoside derivatives
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
EP1752469A3 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties